Lafarge, Maxime W. http://orcid.org/0000-0001-9235-783X
Domingo, Enric http://orcid.org/0000-0003-4390-8767
Sirinukunwattana, Korsuk
Wood, Ruby
Samuel, Leslie http://orcid.org/0000-0002-8402-8670
Murray, Graeme
Richman, Susan D. http://orcid.org/0000-0003-3993-5041
Blake, Andrew http://orcid.org/0000-0002-8154-6253
Sebag-Montefiore, David
Gollins, Simon
Klieser, Eckhard
Neureiter, Daniel
Huemer, Florian
Greil, Richard
Dunne, Philip http://orcid.org/0000-0001-9160-283X
Quirke, Philip http://orcid.org/0000-0002-3597-5444
Weiss, Lukas http://orcid.org/0000-0002-2174-5613
Rittscher, Jens
Maughan, Tim
Koelzer, Viktor H. http://orcid.org/0000-0001-9206-4885
Article History
Received: 7 December 2023
Accepted: 13 March 2024
First Online: 9 April 2024
Competing interests
: V.H.K.: invited speaker for Sharing Progress in Cancer Care (SPCC) and Indica Labs; advisory board of Takeda; sponsored research agreements with Roche and IAG all unrelated to the current study; participant of a patent application on the assessment of cancer immunotherapy biomarkers by digital pathology; a patent application on multimodal deep learning for the prediction of recurrence risk in cancer patients, and a patent application on predicting the efficacy of cancer treatment using deep learning. J.R. and K.S.: co-founders of the Oxford University spinout company Ground Truth Labs (GTL); G.T.L. uses computational pathology to provide biopharma services. T.M.: consultant for GTL. F.H.: honoraria from Pierre Fabre, Amgen, Servier, Daiichi Sankyo, BMS, Merck, Sanofi; travel support from Servier, BMS, Roche, Merck, Pharmamar, Pfizer, Pierre Fabre, Sanofi, Daiichi Sankyo, Gilead; scientific advisory role for Servier, Daiichi Sankyo, BMS; holds stock options in Guardant Health. D.N.: consultant for Boerhinger Ingelheim, Lilly. All other authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.